Analysts’ Recent Ratings Updates for Inari Medical (NARI)

Posted by Anthony Miller on Nov 13th, 2024

Several brokerages have updated their recommendations and price targets on shares of Inari Medical (NASDAQ: NARI) in the last few weeks:

10/29/2024 – Inari Medical had its price target raised by analysts at Robert W. Baird from $66.00 to $67.00. They now have an “outperform” rating on the stock.
10/29/2024 – Inari Medical had its price target raised by analysts at Piper Sandler from $50.00 to $52.00. They now have a “neutral” rating on the stock.
10/29/2024 – Inari Medical had its price target raised by analysts at Truist Financial Co. from $46.00 to $50.00. They now have a “hold” rating on the stock.
10/29/2024 – Inari Medical had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
10/29/2024 – Inari Medical had its price target raised by analysts at Canaccord Genuity Group Inc. from $71.00 to $74.00. They now have a “buy” rating on the stock.
10/14/2024 – Inari Medical had its price target lowered by analysts at Truist Financial Co. from $55.00 to $46.00. They now have a “hold” rating on the stock.
10/9/2024 – Inari Medical had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
9/17/2024 – Inari Medical is now covered by analysts at Stifel Nicolaus. They set a “hold” rating and a $50.00 price target on the stock.

Inari Medical Trading Down 3.8 %

Shares of NASDAQ NARI opened at $51.30 on Wednesday. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $67.13. The company has a 50 day simple moving average of $44.78 and a two-hundred day simple moving average of $46.81. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of -38.00 and a beta of 0.96.

Insider Activity at Inari Medical

In related news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.05, for a total value of $2,002,000.00. Following the completion of the transaction, the director now directly owns 561,233 shares in the company, valued at $28,089,711.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 445,310 shares in the company, valued at $22,265,500. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.05, for a total transaction of $2,002,000.00. Following the completion of the sale, the director now directly owns 561,233 shares of the company’s stock, valued at approximately $28,089,711.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 126,000 shares of company stock worth $5,921,390 in the last three months. Company insiders own 10.60% of the company’s stock.

Institutional Investors Weigh In On Inari Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bessemer Group Inc. increased its holdings in Inari Medical by 16.4% in the 1st quarter. Bessemer Group Inc. now owns 2,439 shares of the company’s stock worth $117,000 after acquiring an additional 344 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Inari Medical by 7.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock worth $234,000 after acquiring an additional 348 shares in the last quarter. Arizona State Retirement System increased its holdings in Inari Medical by 2.5% in the 2nd quarter. Arizona State Retirement System now owns 14,602 shares of the company’s stock worth $703,000 after acquiring an additional 358 shares in the last quarter. Covestor Ltd increased its holdings in Inari Medical by 30.2% in the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after acquiring an additional 376 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after acquiring an additional 435 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.